Clinical utility of circulating cell-free Epstein–Barr virus DNA in patients with gastric cancer by Shoda, Katsutoshi et al.
Oncotarget28796www.impactjournals.com/oncotarget
Clinical utility of circulating cell-free Epstein–Barr virus DNA in 
patients with gastric cancer
Katsutoshi Shoda1, Daisuke Ichikawa1, Yuji Fujita1,2, Kiyoshi Masuda2, Hidekazu 
Hiramoto1, Junichi Hamada1, Tomohiro Arita1, Hirotaka Konishi1, Toshiyuki 
Kosuga1, Shuhei Komatsu1, Atsushi Shiozaki1, Kazuma Okamoto1, Issei Imoto2, 
Eigo Otsuji1
1Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 
602-8566, Japan
2Department of Human Genetics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770-8503, 
Japan
Correspondence to: Daisuke Ichikawa, email: ichikawa@koto.kpu-m.ac.jp
Issei Imoto, email: issehgen@tokushima-u.ac.jp
Keywords: gastric cancer, Epstein–Barr virus, liquid biopsy
Received: October 29, 2016    Accepted: February 6, 2017    Published: February 24, 2017
Copyright: Shoda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
(CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
Recent comprehensive molecular subtyping of gastric cancer (GC) identified 
Epstein–Barr virus (EBV)-positive tumors as a subtype with distinct salient molecular 
and clinical features. In this study, we aimed to determine the potential utility of 
circulating cell-free EBV DNA as a biomarker for the detection and/or monitoring of 
therapeutic response in patients with EBV-associated gastric carcinoma (EBVaGC). 
The EBV genes-to-ribonuclease P RNA component H1 ratios (EBV ratios) in the GC 
tumors and plasma samples were determined by quantitative real-time polymerase 
chain reaction in 153 patients with GC, including 14 patients with EBVaGC diagnosed 
by the conventional method. Circulating cell-free EBV DNA was detected in 14 
patients with GC: the sensitivity and specificity of detection were 71.4% (10/14) 
and 97.1% (135/139), respectively. Plasma EBV ratios were significantly correlated 
with the size of EBVaGC tumors, and the plasma EBV DNA detected before surgery 
in EBVaGC cases disappeared after surgery. Patients with EBVaGC may have a better 
prognosis, but circulating cell-free EBV DNA had no or little impact on prognosis. In 
addition, repeated assessment of the plasma EBV ratio in EBVaGC showed a decrease 
and increase in plasma EBV DNA after treatment and during tumor progression/
recurrence, respectively. These results suggest the potential utility of circulating 
cell-free DNA to reveal EBV DNA for the identification of the EBVaGC subtype and/
or for real-time monitoring of tumor progression as well as treatment response in 
patients with EBVaGC.
INTRODUCTION
Gastric cancer (GC) is the fifth most commonly 
diagnosed cancer and the third leading cause of cancer-related 
mortality worldwide [1]. Recent comprehensive studies 
have characterized GC as a heterogeneous disease, and its 
molecular classification has become a major concern in GC 
research with respect to using it as a guide for developing 
curative targeted agents against GC. One type of GC is 
Epstein–Barr virus (EBV)-associated gastric carcinoma 
(EBVaGC), which has been classified as the molecular 
subtype of tumors positive for EBV in The Cancer Genome 
Atlas project [2] and enriched in the molecular subtype 
of microsatellite stable/TP53-active tumors by the Asian 
Cancer Research Group [3]. Because the high programmed 
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death ligand 1/2 expression and immune pathway activation 
signature in EBVaGCs strongly justify targeting these 
molecules/pathways via immunotherapy, the diagnostic 
screening and monitoring of EBVaGC might prove fruitful 
in selecting candidates for immunotherapy [4].
To date, it has been shown that “liquid biopsy” 
using circulating cell-free DNA (cfDNA) could constitute 
a new paradigm for the study of clonal evolution in 
human cancers [5]. We previously demonstrated the 
potential utility of cfDNA as a resource for a repeatable 
and noninvasive evaluation of the human epidermal 
growth factor receptor 2 amplification status in GC [6, 
7]. Although monitoring circulating cell-free EBV DNA 
can be an effective method for distinguishing disease-
associated EBV reactivation from incidental presence of 
EBV in benign B lymphocytes as well as for diagnostic 
screening and monitoring of EBV-associated diseases 
such as Hodgkin's lymphoma, Burkitt's lymphoma, and 
nasopharyngeal carcinoma [8–10], little has been done 
to evaluate the role of EBV testing in the diagnosis and 
monitoring of GC [11]. In EBVaGC, all tumor cells harbor 
the clonal EBV genome [12], suggesting that the EBV 
genome is useful as a reliable and specific biomarker of 
cancer cells as common founder mutations. Indeed, the 
possibility of using circulating EBV DNA as a tumor 
marker for EBVaGC has been reported [13]. However, no 
studies have examined the dynamics of circulating EBV 
DNA during the clinical course in GC to determine its 
clinical significance in the diagnosis and monitoring of 
EBVaGC.
Therefore, in the present study, we attempted to 
quantitatively detect circulating cell-free EBV DNA in 
the plasma of GC patients (the primary endpoint) and 
examin its clinical potential as a tool for the diagnosis of 
EBVaGC and repeatable and non-invasive monitoring of 
tumor progression and therapeutic effects in patients with 
EBVaGC (the secondary endpoint).
RESULTS
Detection of EBV DNA in tumor tissues and 
plasma samples of GC patients using real-time 
quantitative polymerase chain reaction (rqPCR)
In the paraffin-embedded tissue sections, the 
established assay for EBV targets EBV-encoded small 
RNAs (EBER) by in situ hybridization (ISH). Among a 
total of 153 GC patients (Table 1), 14 were EBER positive 
(Supplementary Figure 1A). A previous study showed 
that EBV DNA levels generally reflect the EBER status, 
and a panel of at least two rqPCR assays is recommended 
for the sensitive identification of the infected cancers 
[14]. Therefore, latent membrane protein 1 (LMP1) and 
Epstein–Barr nuclear antigen 1 (EBNA1) levels were 
assessed to detect the presence of EBV DNA, and EBV 
DNA positivity was defined as a positive result in both 
the rqPCR assays. EBV DNA was detected in 21 GC 
tissue samples by rqPCR, including all 14 cases showing 
EBER positivity in ISH (sensitivity = 1.000, specificity 
= 0.677; Supplementary Figure 1B), whereas EBV DNA 
was not detected in all 153 non-tumorous gastric tissue 
samples of patients with GC. Detection for plasma EBV 
DNA was negative in all 50 healthy volunteers, whereas 
EBV DNA was positively identified in 14 patients with 
GC, ten of which had EBVaGC (sensitivity = 0.714, 
specificity = 0.971; Supplementary Figure 1B). Plasma 
LMP1 DNA was detected in 15 GC cases, including all 14 
cases positive for plasma EBNA1 DNA (Supplementary 
Table 1). EBV DNA was not detected in the peripheral 
blood leukocytes of the 14 EBVaGC patients. In the ten 
patients positive for EBV DNA in both the GC tumor and 
plasma samples, the plasma EBV ratios were significantly 
correlated with the tissue EBV ratios (ρ = 0.7576, p = 
0.011, Spearman’s analysis, Supplementary Figure 2).
Relationships between clinicopathological factors 
and plasma EBV ratios determined by rqPCR
The relationships between clinicopathological 
characteristics and plasma and tumor EBV DNA 
positivities in all 153 patients with GC are summarized 
in Table 1. A positive identification of EBV DNA in the 
plasma was associated with older patients; EBER-positive 
GC tumors were more frequently observed in older GC 
patients in our cohort (Supplementary Table 1). Positive 
identifications of plasma EBV DNA tended to be inversely 
correlated with venous invasion and N stage because 
EBER-positive GC tumors also showed a similar tendency 
(Supplementary Table 1). Notably, positive identifications 
of plasma EBV DNA tended to be positively correlated 
with tumor size; however, positive identifications of tissue 
EBV DNA and EBER did not show this tendency (Table 1, 
Supplementary Table 2). All four EBER-positive cases, in 
which plasma EBV DNA was not detected, were smaller 
than 70 mm (Supplementary Table 3). A similar tendency 
was observed between size and plasma EBV DNA status 
in tumor EBV DNA positive cases (Supplementary 
Table 3). In the ten cases with positive identification of 
both plasma EBV and tumor EBER, plasma EBV ratios 
were highly and significantly correlated with tumor 
sizes (ρ = 0.600 and p = 0.0169, Spearman’s correlation; 
Figure 1A); however, tumor EBV ratios did not show this 
relationship (ρ = 0.3939, p = 0.2600), suggesting that the 
amount of cfDNA from EBV-positive tumors increases 
in a tumor size dependent manner. In the total of 153 
cases, the median follow-up period after surgery was 31 
months (range = 5–85 months). There was no significant 
difference in the overall survival (OS) and recurrence-
free survival (RFS) between the plasma EBV-positive and 
plasma EBV-negative patients (Figure 1B), although OS 
rates were significantly higher in patients with EBVaGC 
in GC tissue (Supplementary Figure 3).
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Table: 1 Clinicopathological features of 153 gastric cancer (GC) patients with analysis of Epstein-Barr virus (EBV)
Variables n Tumor EBV DNAa Plasma EBV DNAb
Negative (%) Positive (%) P value Negative (%) Positive (%) P value
Total 153 132 (86.3) 21 (13.7) 139 (90.8) 14 (9.2)
Sex
 Male 95 80 (84.2) 15 (15.8)
0.2424
84 (88.4) 11 (11.6)
0.1477
 Female 58 52 (89.7) 6 (10.3) 55 (94.8) 3 (5.2)
Age (years)
 <70 83 76 (91.6) 7 (8.4)
0.0331 
79 (95.2) 4 (4.8)
0.0405 
 >70 70 56 (80.0) 14 (20.0) 60 (85.7) 10 (14.3)
Location
 Upper 57 47 (82.5) 10 (17.5)
0.2961
50 (87.7) 7 (12.3)
0.2259
 Middle or lower 96 85 (88.5) 11 (11.5) 89 (92.7) 7 (7.3)
Histopathological 
predominancec 
 Differenciated 79 72 (91.1) 7 (8.9)
0.0576
75 (94.9) 4 (5.1)
0.0621
 Undifferenciated 74 60 (81.1) 14 (18.9) 64 (86.5) 10 (13.5)
Size (mm)
 <70 76 65 (85.5) 11 (14.5)
0.4870
72 (94.7) 4 (5.3)
0.0834
 >70 77 67 (87.0) 10 (13.0) 67 (87.0) 10 (13.0)
Lymphatic invasion
 negative 37 30 (81.1) 7 (18.9)
0.2138
31 (83.8) 6 (16.2)
0.0875
 positive 116 102 (87.9) 14 (12.1) 108 (93.1) 8 (6.9)
Venous invasion
 negative 54 44 (81.5) 10 (18.5)
0.1524
46 (85.2) 8 (14.8)
0.0691
 positive 99 88 (88.9) 11 (11.1) 93 (93.9) 6 (6.1)
Depth of tumor 
invasiond
 pT1/2/3 83 69 (83.1) 14 (16.9)
0.1602
73 (88.0) 10 (12.0)
0.1415
 pT4 70 63 (90.0) 7 (10.0) 66 (94.3) 4 (5.7)
N staged
 pN0 33 26 (78.8) 7 (21.2)
0.1315
27 (81.8) 6 (18.2)
0.0520
 pN1-3 120 106 (88.3) 14 (11.7) 112 (93.3) 8 (6.7)
pStaged
 pI/pII 56 48 (85.7) 8 (14.3)
0.5297
50 (89.3) 6 (10.7)
0.4058
 pIII 97 84 (86.6) 13 (13.4) 89 (91.8) 8 (8.2)
Tissue EBERe
 Negative 139 132 (95.0) 7 (5.0)
<0.0001
135 (97.1) 4 (2.9)
<0.0001
 Positive 14 0 (0.0) 14 (100.0) 4 (28.6) 10 (71.4)
(Continued )
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Dynamics of the plasma EBV ratio during 
therapeutic course
Plasma EBV ratios were comparable between pre- 
and paired post-operative samples in nine of 14 plasma 
EBV-positive cases. All nine cases showed positive 
results for both plasma EBV and tumor EBER. The ratios 
in the post-operative samples were also significantly 
lower than those in the pre-operative samples (n = 9; p 
< 0.0001, paired Wilcoxon t-test), and none of the post-
operative plasma samples were positive for EBV DNA 
(Figure 2), thereby supporting the reproducibility of the 
rqPCR-based measurement for quantitative evaluation of 
cell-free EBV DNA. In addition, this result also supports 
that the plasma EBV ratio reflects the tumor burden of 
EBVaGC.
We performed repeated measurements of the 
plasma EBV ratio before and after surgery in one patient 
with recurrence of EBVaGC, and compared those 
results with the patient’s clinical history (Figure 3). 
In this case, the increase in the plasma EBV ratio was 
detected before operation, and the plasma EBV was not 
continuously detected after surgery. The increase in the 
plasma EBV ratio was detected a month before clinically 
apparent recurrence, and positivity for plasma EBV was 
continuously observed during the progression of metastatic 
tumors with little or no response to chemotherapy. The 
recurrent tumor was indicated by Positron Emission 
Tomography (PET) and cytopathological examination 
of the pleural fluid, with EBV DNA also detected in the 
pleural fluid. The levels of the conventional tumor marker 
CA19-9 were continuously lower than the cut-off values, 
and carcinoembryonic antigen (CEA) was not reflected 
in the dynamics of tumor progression during the entire 
clinical course. This result suggested that plasma EBV 
DNA is a sensitive marker for recurrence in patients with 
EBVaGC.
DISCUSSION
The concept of detecting tumor-specific molecular 
alterations by analyses of bodily fluids, including 
peripheral blood, in cancer patients is termed “liquid 
biopsy” [15]. This new concept is expected to not only 
provide noninvasive diagnostic methods but also realize 
real-time monitoring of tumors by overcoming the issue of 
tumor heterogeneity in cancer care. In the present study, we 
utilized circulating cfDNAs in the plasma samples for the 
detection of EBV-related DNA because the major sources 
of cfDNA are considered to be the apoptotic and necrotic 
cells in tumors. The plasma EBV DNA was detected in 
10 of 14 patients with EBVaGC but was not detected in 
135 of 139 non-EBVaGC patients and all 50 healthy 
volunteers, as previously reported [13]. All four tumor 
EBER-positive cases, which showed negative plasma EBV 
DNA, were smaller than 70 mm in size, and significant 
correlation was observed between the tumor size and the 
plasma EBV ratio in plasma EBV DNA-positive patients 
with EBVaGC, which suggests that the amounts of cfDNA 
from GC cells in some of the smaller EBVaGC tumors 
were not sufficient to detect EBV DNA using rqPCR. 
However, the copy number of episomal EBV DNA in GC 
Variables n Tumor EBV DNAa Plasma EBV DNAb
Negative (%) Positive (%) P value Negative (%) Positive (%) P value
Tumor EBV DNAa
 Negative 132 - - 128 (97.0) 4 (3.0)
<0.0001
 Positive 21 - - 11 (52.4) 10 (47.6)
Plasma EBV DNAb
 Negative 139 128 (92.1) 11 (7.9)
<0.0001
- -
 Positive 14 4 (28.6) 10 (71.4) - -
P  values are from χ2 or Fisher's exact test and the results were considered statistically significant at P < 0.05. Statistically 
significant values are in boldface type.
a Tumor EBV DNA was determined by rqPCR using LMP1 and EBNA1 primers.
b  Plasma EBV DNA was determined by real-time quantitative polymerase chain reaction (rqPCR) using latent membrane 
protein 1 (LMP1) and Epstein-Barr nuclear antigen 1 (EBNA1) primers.
c  Differentiated: tubular adenocarcinoma or papillary adenocarcinoma.
 Undifferentiated: poorly differentiated adenocarcinoma, signet-ring carcinoma, or mucinous adenocarcinoma.
d  Disease stage was defined in accordance with the International Union Against Cancer 7th tumor-lymph node-metastases 
classification using surgical-pathologic findings.
e  Tissue EBV was determined by in situ hybridization as described in the text.
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cells in each tumor is also the factor associated with the 
amount of cell-free EBV DNA from tumors. Therefore, 
the quantitative detection of cell-free EBV DNA in the 
plasma sample reflects tumor burden, and any method with 
higher sensitivity might allow more accurate detection of 
EBVaGC tumors. Four cases with negative EBER ISH 
and EBV DNA in GC tissues were positively identified 
for plasma EBV DNA. A previous study suggested the 
possibility that EBV could infect the noncarcinomatous 
gastric mucosa of chronic atrophic gastritis [13, 16]. A 
possibility exists that such nonspecific EBV infection had 
an influence on the discrepancy, although none of 153 
cases of GC were positively identified for tumor EBV DNA 
in non-tumorous stomach tissues.
Figure 1: Potential of plasma Epstein-Barr virus (EBV) ratio for use in the detection of EBV DNA in cell-free DNA 
(cfDNA) samples. (A) Relationship between tumor size and the EBV ratio in patients with gastric cancer (GC). Red and blue circles 
represent plasma and tumor EBV ratios for each patient, respectively. Plasma EBV ratios were significantly correlated with tumor sizes 
in patients with GC (ρ = 0.600, p = 0.0169, Spearman’s correlation); however, tumor EBV ratios were not (ρ = 0.3939, p = 0.2600). 
RQ; relative quantitative value. (B) Kaplan-Meier curves for recurrence-free survival rates (left) and overall survival rates (right) of GC 
patients according to the presence of EBV DNA in the plasma. The log-rank test was used for statistical analysis. P < 0.05 was considered 
statistically significant.
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The EBV DNA was not detected in the 
postoperative plasma samples in all EBVaGC patients 
tested positive for preoperative plasma EBV DNA, 
indicating that our rqPCR-based detection of plasma 
EBV DNA is a highly specific method for monitoring 
response to treatment for EBVaGC. Although the 
stability of cfDNA is not well understood, circulating 
cfDNA appears to be rapidly cleared; the mean half-
Figure 3: Longitudinal analysis of the clinical history of a case whose plasma Epstein-Barr virus (EBV) ratio was 
monitored repeatedly before and after surgery. A 73-year-old male patient underwent surgery for gastric cancer of pathological 
stage T1, N0, M0, and stage IA. His plasma EBV ratio was high before surgery, and a decreased level was maintained until a month before 
pleura dissemination was diagnosed by positron emission tomography (right lower). EBV DNA was also detected in the pleural fluid at the 
time of recurrence (right upper). Note that neither carcinoembryonic antigen nor serum carbohydrate associated antigen values reflect the 
clinical history in this case.
Figure 2: Dynamics of the plasma Epstein-Barr virus (EBV) ratio before and after surgery. Sets of plasma cfDNA before 
and after surgery were available for nine patients with EBVaGC showing positive results of pre-operative plasma EBV DNA. Squares and 
circles represent tumors ≥70 mm and those <70 mm, respectively. Black, red, and blue colors indicate pathological stages (pStage) I, II, 
and III, respectively.
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life of cell-free fetal DNA was previously estimated 
to be 16 min [17] and more recently to be 1 h in the 
initial rapid phase and 13 h in the subsequent slow 
phase [18]. A study regarding the kinetics and clearance 
of circulating EBV DNA may indicate equivalent 
mechanisms in the EBV-related tumor, such as 
nasopharyngeal carcinoma [19].
In comparison with the results of EBER analysis 
by ISH, the EBV DNA analysis of tissues showed a 
higher positivity rate. All the EBER-positive cases 
were positively identified for tissue EBV DNA, and an 
additional seven cases were found to only have EBV DNA 
in tumor samples. Although methods for targeting EBV 
DNA using two rqPCR assays are known to reflect the 
EBER status with a high sensitivity and specificity [14], 
the difference in sensitivity between the ISH and rqPCR 
assays might be one of the reasons responsible for this 
discrepancy, and rqPCR targeting episomal EBV DNA 
might detect latent EBV DNA in some cases of GC.
Our prognostic analysis demonstrated that there 
was no significant difference in the OS and RFS between 
plasma EBV-positive and -negative patients, whereas the 
presence of EBV in GC tissue had a favorable impact on 
the OS of GC patients, although effects on OS and RFS 
were opposite. Although EBVaGC has been reported to 
present a relatively favorable prognosis in the Asian 
population [20] and international analysis [21], the 
prognostic significance of EBVaGC remains controversial 
[22]. In a clinicopathological study in the Netherlands, 
cases of EBVaGC showed a better prognosis than negative 
cases [23]. In the present study, EBVaGC accompanied 
lymph node metastasis in a significantly lower frequency 
than EBV-negative GC (Supplementary Table 2), 
suggesting that cases of EBVaGC may have a better 
prognosis, although the numbers of cases were insufficient 
for prognostic analysis in previous studies as well as our 
cases. Although it remains unclear why circulating cell-
free EBV DNA had no or little impact on prognosis in GC, 
it is possible that EBVaGC cases associated with better 
prognosis were included in plasma EBV-negative cases. 
Indeed, all four plasma EBV-negative EBVaGC cases 
had tumors smaller than 70 mm and relatively longer OS 
with no death in the observation period (range, 1.07–3.50 
years; median, 1.46 years). Further study using a larger 
and independent cohort will be required to determine the 
prognostic impact of EBVaGC, as well as the plasma EBV 
DNA measurement.
The plasma EBV ratio decreased immediately 
after surgery, was elevated before an expression of 
markers found in various diagnostic imaging tools, 
and continuously increased with the progression of 
recurrent disease (Figure 3). These results indicate 
that the detection of plasma EBV in EBVaGC reflects 
tumor burden and could be a sensitive and repeatable 
marker for tumor progression and therapeutic effect for 
patients with EBVaGC at a low cost (reagent cost, <10 
dollars per test), although its usefulness was proven only 
in one patient. Further studies using a larger number 
of EBVaGC patients and a prospective study design 
are required in the future. In addition, more sensitive 
methods without increasing the cost should be developed 
to monitor tumor burden repeatedly in EBVaGC patients 
as a clinical test.
MATERIALS AND METHODS
Patients and samples
The present study was performed in accordance with 
the Declaration of Helsinki protocols and was approved 
by the local Ethics Committee. All the subjects gave 
their written informed consent before participating. The 
samples were blinded for analyses and the patients were 
informed that the results would not be made available to 
them. The study cohort included 153 GC patients who 
underwent surgery, through which both tumor and plasma 
samples were collected between January 2008 and October 
2014 at the Kyoto Prefectural University of Medicine 
Hospital (Table 1). Control plasma samples were obtained 
from 50 healthy adult volunteers by standard antecubital 
venous punctures. Patient demographic data and details 
regarding tumor recurrence and subsequent management 
were recorded. Computed tomography (CT) imaging was 
performed and reviewed in a blinded manner to document 
treatment responses according to the Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.1 [24]. The 
pathological classification of the tumors was performed 
according to the Union for International Cancer Control 
classification [25].
Sample preparation and DNA isolation
A 7 mL ethylenediaminetetraacetic acid-blood 
sample was obtained from each patient before surgery 
and from 50 healthy volunteers. Samples were also 
collected from nine patients one month after surgery 
and from one patient during the post-operative period. 
The plasma was immediately separated from the 
cellular fraction using a three-spin protocol as described 
previously [26], following which the samples were stored 
at −80°C for further processing. Circulating cfDNA 
was isolated from 2 mL of the plasma sample using the 
QIAamp Circulating Nucleatic Acid Kit (Qiagen, Hilden, 
Germany). Genomic DNA from the cancerous gastric 
tissues was extracted from three slices (5 µm thick) of 
formalin-fixed, paraffin-embedded (FFPE) tissues using 
the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocols. 
We also extracted genomic DNA from peripheral blood 
leukocytes using the Gentra Puregene Blood Kit (Qiagen, 
Hilden, Germany).
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In situ hybridization (ISH) of EBV-encoded 
small RNAs (EBER)
Two adjacent sections were stained with 
hematoxylin and eosin by ISH for EBER with the 
inclusion of known EBER-positive and -negative tumors 
as external controls. Hybridization was performed using 
the Leica Bond system with 5 min of protease digestion 
and 2 h of probe hybridization. A tumor was interpreted 
as EBV negative if EBER staining was undetected or only 
localized to benign-appearing lymphoid cells, and as EBV 
positive if EBER staining was localized to the nucleus of 
malignant epithelial cells [14]. EBER-positive patients 
were determined to have EBVaGC.
Quantitative analysis of EBV DNA using real-
time quantitative polymerase chain reaction 
(rqPCR)
All rqPCR amplifications were performed in 
triplicate using the Applied Biosystems® Step one Real 
Time PCR system (Life Technologies, Carlsbad, CA, 
USA) according to the manufacturer’s protocols. Using 
ribonuclease P RNA component H1 (RPPH1) as an 
internal control for the quantitative analysis of EBV DNA 
[6, 7], plasma EBNA1-to-RPPH1 and plasma LMP1-to-
RPPH1 ratios were determined using the rqPCR assays. 
To determine EBV ratio, the ΔCt value (average Ct value 
of the target gene minus the average Ct value of the 
reference gene) was determined and used to calculate the 
ΔΔCt value for each DNA sample with a mean relative 
quantitation (RQ) value. RQ values were calculated from 
2−ΔΔCt. EBV positivity was defined as the case wherein 
the Ct values of both target genes were detectable, that 
is, if the any Ct value was undetectable, the case was 
considered to be EBV negative. Only in cases positive for 
tissue or plasma EBV DNA, the tissue or plasma EBV 
ratio was calculated using the average of the EBNA1-to-
RPPH1 ratio and the plasma LMP1-to-RPPH1 ratio.
The following primers were used for the 
rqPCR assays: LMP1 forward (5′-CAGTCAGGCA 
AGCCTATGA-3′), LMP1 reverse (5′-CTGGTTCCGG 
TGGAGATGA-3′), the FAM probe for LMP1 (5′-FAM- 
GTCATAGTA GCTTAGCTGAAC-3′), EBNA1 forward 
(5′-TACAGGACCTGGAAATGGCC-3′), EBNA1 
reverse (5′-TCTTTGAGGTCCACTGCCG-3′), the FAM 
probe for EBNA1 (5′-FAM- AGGGAGACACATC 
TGGACCAGAAGGC-3′), RPPH1 forward (5′- GTCAG 
ACTGGGCAGGAGATG-3′), RPPH1 reverse (5′-TGGC 
CGTGAGTCTGTTCC-3′), and the HEX probe for 
RPPH1 (5′-HEX- TGCCTCCTTTGCCGGAGCTT-3′). 
The final PCR mixture (10 µl) contained 5 µl of TaqMan 
universal PCR master mix (Life Technologies), 3 µl of a 
DNA sample, 1 µl of mixture of RPPH1 primer, and 1 µl 
of mixture of LMP1 or EBNA1 primer.
Statistical analysis
Spearmanʼs correlation coefficients were determined 
to assess the relationships between the EBV DNA data 
determined by different methods. Nonparametric tests 
were performed for subgroup comparisons (Wilcoxon 
rank-sum test) and for comparisons between paired 
samples in each subgroup (Wilcoxon signed-rank 
test). A χ2 test or Fisher’s exact test was performed 
to assess associations between the EBV status and 
clinicopathological factors. All statistical tests except for 
the paired tests were two-sided. OS and RFS rates were 
calculated by the Kaplan–Meier method with the date of 
gastrectomy as the starting point. Differences in survival 
rates were examined by the log-rank test. P < 0.05 was 
considered statistically significant.
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